Plus Therapeutics (NASDAQ:CNSY – Get Free Report) posted its earnings results on Friday. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35), Zacks reports. Plus Therapeutics had a negative net margin of 230.24% and a negative return on equity of 198.48%.
Plus Therapeutics Trading Down 0.5%
Shares of NASDAQ:CNSY opened at $3.68 on Friday. Plus Therapeutics has a 12 month low of $2.90 and a 12 month high of $23.42. The firm has a market cap of $25.32 million, a P/E ratio of -1.10 and a beta of 1.42.
Wall Street Analyst Weigh In
A number of equities research analysts have recently commented on CNSY shares. Zacks Research lowered Plus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. Weiss Ratings began coverage on Plus Therapeutics in a research report on Tuesday, August 4th. They issued a “sell (e+)” rating for the company. Two analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Plus Therapeutics Company Profile
Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.
Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.
Featured Stories
- Five stocks we like better than Plus Therapeutics
- AMG’s Alternatives Boom Powers Record Growth
- Microsoft’s Maia 300 Chip Targets NVIDIA’s AI Dominance
- 3 Unexpected ETFs Crushing the Market This Summer
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
